|
 |
BioPortfolio
Bulletin
|
| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_47.htm
July
13 2004
|
|
Lead
Sponsor:
 |
|
Biotech
industry expert Dr. Ron Garren analyzes newsworthy events in the medical
marketplace and places them in the context of value to the investor.
Through his website, he distributes frequent email alerts to
subscribers. An archive of past alerts, along with a model portfolio of
biotech stocks is also available.
http://www.biotechinsight.com/ |
|
In
this Week's issue:
1) Biotech industry expert Dr.
Ron Garren analyzes newsworthy events - see
above
2) Bioterrorism,
Anthrax and Smallpox Information Resources
3) Pharmaceutical
Pricing Strategies: Optimizing
returns throughout R&D and marketing 3 for
2 offer
4) New
Reports:
- Analytical
Tool Competitive Outlook on HCV
- Analytical
Tool: Frontlines in Cancer Therapeutics I
- Model
Animal Systems Emerging Applications and Commercial Opportunities in
Drug Discovery and Development
- Evaluating
Online Advertising Opportunities Life Science Portals
4)
Emerging Drug Discovery - Scientific Publication Alerts
5) BioWatch
News Email Alerts
|
|
| Bioterrorism,
Anthrax and Smallpox Information Resources |
| View
reports:
|
|
BioPortfolio
have created a unique web index - please evaluate:
|
| Pharmaceutical
Pricing Strategies: Optimizing
returns throughout R&D and marketing |
 |
|
Special
Offer: Save up to $1199.00
The
latest pricing report from Reuters Business Insight ‘Pharmaceutical
Pricing Strategies: Optimizing returns throughout R&D and
marketing’ investigates the global pricing of pharmaceutical and
biotechnology products allowing you to strengthen your competitive
strategy and map out the future scenarios which could affect your
company. This report provides a framework for devising an optimal
pricing strategy to enable you to maximize the returns from new and
established products. See detail at:
http://www.bioportfolio.com/cgi-bin/acatalog/Reuters_2003.html#a167
Discover
whether your predictions of trends in pharmaceutical pricing are
consistent with key industry analysts’ and determine how your company
will deal with the impact of these trends, with the help of this
management report.
Special Offer: Save up to $1199.00
Order your copy of
‘Pharmaceutical Pricing Strategies’ before Friday 23rd July 2004,
and receive ’Pharmaceutical Portfolio Management’ and ‘The
Pharmaceutical Parallel Trade Outlook’ for half price.
Email
peter.barfoot@bioportfolio.com
today
Reuters Business
Insight reports are published by Datamonitor, in association with
Reuters. Reuters, the sphere logo and Reuters Business Insight are trade
marks of the Reuters group of companies around the world and are used by
Datamonitor under licence from Reuters
|
| New
Reports: |
|
|
|
Analytical
Tool Competitive Outlook on HCV
BioSeeker Group's
"Analytical Tool: Competitive Outlook on HCV", represents a
powerful product combination of the independent and unbiased analytical
report Competitive Outlook on HCV: What to Know & Expect in R&D
and Business Development and the HCV R&D and Business Development
Database, which gives you access to substantial background information
on the subject covered by the report, i.e. company profiles, R&D
projects, and business collaborations. To order click:
http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker.html#a679
|
|
|
|
Analytical
Tool: Frontlines in Cancer Therapeutics I
In this very
extensive Analytical Tool, BioSeeker has selected a number of fields and
topics in cancer therapy R&D, which have all seen tremendous
advancements lately. Monoclonal antibodies, anti-angiogenesis / vascular
targeting, protein kinase inhibitors, integrin antagonists, VEGF-Trap
and Endostatin are covered in a number of reports and databases,
included in this Analytical Tool. This range of therapeutic strategies
and targets include many strong interrelationships in terms of
technology, R&D and competition. An example of this is Avastin, a
monoclonal antibody targeting the VEGF signaling pathway, partly
resulting in an antiangiogenetic effect.
With the products included in this
Analytical Tool, you will be guided through some of the most active,
competitive and interesting fields in oncology today. While providing a
complete overview of these topics, this package will also allow you the
opportunity to carry out independent in-depth analysis on these fields,
thanks to the immense and complete data sets included. This Analytical
Tool also forecasts the developmental progress in terms of indications,
type of drugs, drug effects, targets, and mechanism of actions. Hundreds
of companies and their activities are described and evaluated. More than
1000 cancer projects are included. To order click:
http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker.html#a676
|
| |
|
Model
Animal Systems Emerging Applications and Commercial Opportunities in
Drug Discovery and Development
Allan B. Haberman, Ph.D., Haberman Associates, The Biopharmaceutical
Consortium
Contributing Editors: Malorye A. Branca
and Laurie L. Sullivan, Cambridge Healthtech Advisors
Model Animal Systems: Emerging
Applications and Commercial Opportunities in Drug Discovery and
Development reviews the progress in the application of animal models to
drug discovery and development, and discusses the leading companies
providing tools in this field, the areas of greatest unmet need, and the
most important emerging applications. Models discussed include yeast,
the nematode (Caenorhabditis elegans), the fruitfly (Drosophila
melanogaster), the zebrafish (Danio rerio), the mouse, and the rat.
http://www.bioportfolio.com/cgi-bin/acatalog/Cambridge_Healthtech_Advisors.html
|
 |
|
Evaluating
Online Advertising Opportunities Life Science Portals
Commercial life science portals provide users with "one-stop"
access to the information they need and offer a wide array of content
that could be of interest to life science researchers, such as
scientific articles, news briefs, product and supplier information, and
professional resources. These focused, online communities have emerged
not only to encourage repeat visits from scientists, but also to attract
advertising dollars and sponsorships. Online advertising at such web
sites can take a variety of forms—from simple banner ads to paid
content to electronic storefronts. However, given the bewildering array
of life science portals, the question of where to place these ads has
become extremely complex. Based on a 36-question survey of more than
1,300 life scientists, Evaluating Online Advertising Opportunities @
Life Science Portals is designed to help marketers understand
scientists’ perspectives on web content, banner ads and e-newsletters.
By doing so, this report will help life science executives decide where
to spend their advertising budget using the same criteria as their
scientific customers, rather than assessing the value of a portal on the
basis of "hits", "pages served" and "unique
user" statistics.
http://www.bioportfolio.com/cgi-bin/acatalog/copy_of_bioinformatics_1.html#a641
|
| Emerging
Drug Discovery - Scientific Publication Alerts |
|
SUBSCRIBE
HERE
$95.00 per channel per year
|
|
DailyUpdates
was launched in 2002 by the pharmaceutical analysts LeadDiscovery
and represents the first "newsfeed" that identifies breaking
scientific publications with drug development potential.
Using
proprietary data retrieval strategies LeadDiscovery selects
daily 1,000 PubMed articles and press releases. The selected
articles and releases are then scanned by an industrial research panel
which judges those articles considered to be of greatest benefit for
the drug development sector.
Selected
publications as well as press releases are then listed on DailyUpdates
six therapeutic channels that match core R&D areas;
|
| BioWatch
News Email Alerts |
|
News EMAIL alerts - click
here!
|
|
We
have used the BioPortfolio BioWatch News email alert service for two
years to track commercial developments in diabetes, oncology and CNS –
we will be subscribing for a third year because we find it a user
friendly and an excellent vehicle for keeping us aware”. Lester
Salans.
Download
the BioWatch News
Email Alert pdf brochure (100 Kb) and order form!
Subscribe
to BioWatch News alerts - Step 1 of 4
Step 1 - select the type of
subscription:
-
Silver
membership: Allows you to choose up to 10 pre-defined alert
topics - each alert topic costs $25.00 per year. Click
here!
-
Gold membership:
You define the alert topics based on keywords of importance to you -
each personal alert topic costs $50.00 per year. During the
subscription period you can change the search words used for each
topic. To subscribe go directly to Step
4 now!
-
Corporate
membership: Corporate subscribers identify the keywords/topics
of importance and BioPortfolio emails the news alerts for each topic
to a separate email address. The corporate internal email system
then forwards the email alerts to employees who have subscribed to
the respective topic. $200.00 per topic per year for small/medium
biotech organizations and $400.00 per topic per year for large
pharmaceutical organizations. To subscribe email peter.barfoot@bioportfolio.com.
http://www.bioportfolio.com/news_tracking/index.htm
|
Contact
us:
Editorial and features: peter.barfoot@bioportfolio.com
Subscriber
information:
To subscribe for the
BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com
To
unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove your email
address from the list based on your email address. If your
email has changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually unsubscribe for
you. Thank you for your understanding.
©2004
BioPortfolio Limited - http://www.bioportfolio.com
and http://www.bioportfolio.co.uk
|
|
